Back |
home / stock / opht / opht message board
Subject | By | Source | When |
---|---|---|---|
At least 2,40+ holding to FINALLY ;) create | Klinsmann | investorshub | 06/08/2017 1:42:20 PM |
they try to walk it dn every morn | buylow2 | investorshub | 06/08/2017 1:37:45 PM |
one good piece of news, and stock doubles | buylow2 | investorshub | 06/05/2017 6:22:13 PM |
Someone bought 163k shares AH... | Klinsmann | investorshub | 06/03/2017 1:48:38 AM |
In at 2,44, at least a reaction on | Klinsmann | investorshub | 06/02/2017 2:23:42 PM |
Id say today could be a big step, | Klinsmann | investorshub | 06/02/2017 1:36:14 PM |
No one listens to you, so take a hike | SPORTSPROPHET | investorshub | 05/24/2017 5:18:56 PM |
I'll take a stab....calling $2 bottom. Based on | tonyjh | investorshub | 05/24/2017 2:56:01 PM |
If it would be so easy ;) | Klinsmann | investorshub | 05/23/2017 12:51:45 PM |
Looks like it! Been wrong before calling a | naturalborninvestor | investorshub | 05/22/2017 8:51:16 PM |
D. E. SHAW & CO, L.P. has filed | wiltonio | investorshub | 05/22/2017 8:02:01 PM |
Same here! Still on the sidelines - bottom?!?!??? ;) | Klinsmann | investorshub | 05/22/2017 6:19:11 PM |
News, Short Squeeze, Breakout and More Instantly...
Ophthotech Corporation Company Name:
OPHT Stock Symbol:
NASDAQ Market:
Ophthotech Corporation Website:
- Company’s Shares Will Trade Under New Ticker Symbol: ISEE – Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IR...
Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania (Penn), including the Perelman School of Medicine at the University of Pennsylvania and the University ...
Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7 th Annual Cell and Gene Therapy Investor Day in New York, NY, on Thursday, March 21...